{"name":"Novira Therapeutics","permalink":"novira-therapeutics","crunchbase_url":"http://www.crunchbase.com/company/novira-therapeutics","homepage_url":"http://www.noviratherapeutics.com/","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"info@noviratherapeutics.com","phone_number":"781-686-9947","description":"antiviral therapeutics","created_at":"Tue Apr 14 14:39:04 UTC 2009","updated_at":"Fri Aug 24 12:56:59 UTC 2012","overview":"<p>Novira is focused on the discovery and development of first-in-class antiviral therapeutics. Based on emerging biology and proprietary insights on virus-host interactions, the company is working to develop novel small molecule drugs against medically-important viral targets.</p>","image":{"available_sizes":[[[150,39],"assets/images/resized/0014/6325/146325v1-max-150x150.png"],[[250,65],"assets/images/resized/0014/6325/146325v1-max-250x250.png"],[[317,83],"assets/images/resized/0014/6325/146325v1-max-450x450.png"]],"attribution":null},"products":[],"relationships":[],"competitions":[],"providerships":[],"total_money_raised":"$25.5M","funding_rounds":[{"round_code":"seed","source_url":"http://www.noviratherapeutics.com/Novira%20Press%20Release%20July%202011_final.pdf","source_description":"Novira Therapeutics, Inc. Completes Second Round of Seed Financing with Philadelphia Angel Syndicate","raised_amount":2500000,"raised_currency_code":"USD","funded_year":2011,"funded_month":7,"funded_day":26,"investments":[{"company":null,"financial_org":{"name":"Delaware Crossing Investor Group","permalink":"delaware-crossing-investor-group","image":{"available_sizes":[[[150,100],"assets/images/resized/0005/7728/57728v1-max-150x150.png"],[[179,120],"assets/images/resized/0005/7728/57728v1-max-250x250.png"],[[179,120],"assets/images/resized/0005/7728/57728v1-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Robin Hood Ventures","permalink":"robin-hood-ventures","image":{"available_sizes":[[[150,50],"assets/images/resized/0005/7727/57727v1-max-150x150.jpg"],[[250,83],"assets/images/resized/0005/7727/57727v1-max-250x250.jpg"],[[450,150],"assets/images/resized/0005/7727/57727v1-max-450x450.jpg"]],"attribution":null}},"person":null}]},{"round_code":"a","source_url":"http://www.finsmes.com/2012/08/novira-therapeutics-secures-23m-series-financing.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29","source_description":"Novira Therapeutics Secures $23M in Series A Financing","raised_amount":23000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":8,"funded_day":24,"investments":[{"company":null,"financial_org":{"name":"5AM Ventures","permalink":"5am-ventures","image":{"available_sizes":[[[149,105],"assets/images/resized/0004/7316/47316v1-max-150x150.png"],[[149,105],"assets/images/resized/0004/7316/47316v1-max-250x250.png"],[[149,105],"assets/images/resized/0004/7316/47316v1-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Canaan Partners","permalink":"canaan-partners-3","image":{"available_sizes":[[[150,49],"assets/images/resized/0000/3958/3958v4-max-150x150.jpg"],[[250,82],"assets/images/resized/0000/3958/3958v4-max-250x250.jpg"],[[450,147],"assets/images/resized/0000/3958/3958v4-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"BioAdvance","permalink":"bioadvance","image":{"available_sizes":[[[150,43],"assets/images/resized/0005/6697/56697v1-max-150x150.jpg"],[[226,66],"assets/images/resized/0005/6697/56697v1-max-250x250.jpg"],[[226,66],"assets/images/resized/0005/6697/56697v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Mid Atlantic Angel Fund","permalink":"mid-atlantic-angel-fund","image":{"available_sizes":[[[150,35],"assets/images/resized/0004/5145/45145v1-max-150x150.png"],[[200,47],"assets/images/resized/0004/5145/45145v1-max-250x250.png"],[[200,47],"assets/images/resized/0004/5145/45145v1-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Robin Hood Ventures","permalink":"robin-hood-ventures","image":{"available_sizes":[[[150,50],"assets/images/resized/0005/7727/57727v1-max-150x150.jpg"],[[250,83],"assets/images/resized/0005/7727/57727v1-max-250x250.jpg"],[[450,150],"assets/images/resized/0005/7727/57727v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Delaware Crossing Investor Group","permalink":"delaware-crossing-investor-group","image":{"available_sizes":[[[150,100],"assets/images/resized/0005/7728/57728v1-max-150x150.png"],[[179,120],"assets/images/resized/0005/7728/57728v1-max-250x250.png"],[[179,120],"assets/images/resized/0005/7728/57728v1-max-450x450.png"]],"attribution":null}},"person":null}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[],"milestones":[],"ipo":null,"video_embeds":[],"screenshots":[],"external_links":[]}